Sunitinib
Study 1
Pfizer · Phase 3 · Completed · Enrollment 361
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Sunitinib 50 mg, 4 weeks on 2 off | GIST after imatinib progression or intolerance | 50 mg | ITT | placebo | median time to tumor progression: 27.3 weeks, interim analysismedian progression-free survival: 24.1 weeks, interim analysisobjective response rate (partial responses): 6.8%, interim analysis |
| Placebo | GIST after imatinib progression or intolerance | placebo | ITT | n/r | median time to tumor progression: 6.4 weeks, interim analysismedian progression-free survival: 6 weeks, interim analysis |